Other important mutations in CRC involve the activation of proto-oncogenes KRAS and BRAF, inactivation of tumor suppressors TP53 and SMAD4, and alterations in PIK3CA (Phosphatidyl inositol 3-kinase) and TGFBR2 (Transforming growth factor receptor-2) [10]. The gene discussed is KRAS; the disease is colorectal carcinoma.